Co-targeting KRAS G12C and EGFR reduces both mutant and wild-type RAS-GTPThomas McFall, Edward C. Stites|npj Precision Oncology|2022Cited by 16
Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal AdenocarcinomaMandana Kamgar, Thomas McFall|Cancer Research|2025Cited by 2